Sio Capital Management, LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Sio Capital Management, LLC reported 55 stock positions worth $583.5 million. Its top holding was Anteris Technologies Global (AVR) at 9.4% of the portfolio, followed by Cencora (COR, 8.4%) and Maximus (MMS, 6.6%). Compared with Q1 2026, it opened 14 new positions, sold out of 30, added to 10 and reduced 21. The biggest buy was Anteris Technologies Global (AVR, shares +3%) and the biggest sale an exit from Corcept Therapeutics (CORT).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001482416
- Portfolio Value
- $583.5M (Q2 2026)
- SEC Filing
- 0001214659-26-010311 ↗ filed Aug 14, 2026
Holdings Value
Holdings 55 stocks · $583.5M
| AVR Anteris Technologies Global | 9.36% | 5,545,984 | $54.6M | Add +3.0% |
| COR Cencora Inc. | 8.42% | 173,588 | $49.1M | Add +72.0% |
| MMS Maximus Inc. | 6.59% | 715,267 | $38.5M | Reduce -7.0% |
| ALLO Allogene Therapeutics Inc. | 4.75% | 13,323,431 | $27.7M | New |
| GMED Globus Medical Inc. Class A | 4.09% | 301,816 | $23.8M | New |
| GSK GSK PLC-Spon ADR | 3.92% | 436,700 | $22.9M | Add +13.2% |
| TYRA Tyra Biosciences Inc. | 3.81% | 695,315 | $22.2M | Add +14.8% |
| WAY Waystar Holding Corp. | 3.26% | 925,834 | $19.0M | Reduce -43.6% |
| IDYA Ideaya Biosciences Inc. | 3.07% | 480,383 | $17.9M | New |
| ORKA Oruka Therapeutics Inc. | 2.89% | 177,118 | $16.9M | Add +33.7% |
| CI The Cigna Group | 2.73% | 57,750 | $15.9M | New |
| SNY Sanofi-ADR | 2.66% | 364,200 | $15.5M | Add +52.0% |
| ICLR Icon PLC filed as ICON PUB LTD CO | 2.63% | 88,186 | $15.3M | Reduce -71.2% |
| VTRS Viatris Inc. | 2.60% | 954,299 | $15.2M | New |
| CCRN Cross Country Healthcare Inc. | 2.49% | 1,098,393 | $14.5M | No change |
| RAPP Rapport Therapeutics Inc. | 2.20% | 307,657 | $12.8M | Reduce -16.1% |
| ABT Abbott Laboratories | 2.00% | 128,656 | $11.7M | Reduce -31.0% |
| CELC Celcuity Inc. | 1.97% | 110,022 | $11.5M | Reduce -43.2% |
| ZBH Zimmer Biomet Holdings Inc. | 1.94% | 131,445 | $11.3M | Add +109.9% |
| REGN Regeneron Pharmaceuticals | 1.92% | 18,000 | $11.2M | New |
| BMY Bristol-Myers Squibb Co. | 1.91% | 193,500 | $11.1M | New |
| MDT Medtronic PLC | 1.91% | 142,500 | $11.1M | New |
| VIR Vir Biotechnology Inc. | 1.88% | 1,075,274 | $11.0M | Reduce -28.3% |
| SENS Senseonics Holdings Inc. | 1.55% | 1,592,692 | $9.0M | Add +1275.6% |
| EYPT Eyepoint Inc. | 1.53% | 623,130 | $8.9M | Reduce -13.7% |
| HELP Cybin Inc. | 1.47% | 1,300,000 | $8.6M | New |
| ANIP Ani Pharmaceuticals Inc. | 1.38% | 97,305 | $8.1M | Reduce -63.4% |
| TARA Protara Therapeutic Inc. | 1.26% | 1,921,872 | $7.3M | Reduce -2.4% |
| RLMD Relmada Therapeutics Inc. | 1.19% | 1,003,562 | $6.9M | Add +4.0% |
| TNGX Tango Therapeutics Inc. | 1.12% | 208,500 | $6.5M | New |
| AQST Aquestive Therapeutics Inc. | 1.06% | 1,486,175 | $6.2M | Reduce -22.7% |
| DNTH Dianthus Therapeutics Inc. | 0.99% | 59,254 | $5.8M | Reduce -84.0% |
| SION Sionna Therapeutics Inc. | 0.96% | 127,808 | $5.6M | Reduce -56.6% |
| OCUL Ocular Therapeutix Inc. | 0.91% | 539,493 | $5.3M | Reduce -44.3% |
| ZBIO Zenas Biopharma Inc. | 0.91% | 208,557 | $5.3M | Reduce -37.1% |
| DRUG Bright Minds Biosciences Inc. | 0.89% | 73,952 | $5.2M | Reduce -14.1% |
| OKUR Onkure Therapeutics Inc. Class A | 0.84% | 1,078,965 | $4.9M | No change |
| SVRA Savara Inc. | 0.65% | 617,675 | $3.8M | Add +0.6% |
| PMVP PMV Pharmaceuticals Inc. | 0.60% | 2,634,137 | $3.5M | Reduce -14.4% |
| AVAH Aveanna Healthcare Holdings | 0.54% | 369,036 | $3.2M | New |
| OVID Ovid Therapeutics Inc. | 0.46% | 1,005,334 | $2.7M | Reduce -19.7% |
| IMNM Immunome Inc. | 0.45% | 124,168 | $2.6M | Reduce -24.8% |
| ANTX AN2 Therapeutics Inc. | 0.44% | 529,933 | $2.6M | Reduce -19.4% |
| SER Serina Therapeutics Inc. | 0.33% | 1,000,000 | $1.9M | No change |
| ALGS Aligos Therapeutics Inc. | 0.32% | 327,237 | $1.9M | No change |
| IBIO Ibio Inc. | 0.27% | 904,268 | $1.6M | No change |
| XLO Xilio Therapeutics Inc. | 0.25% | 152,464 | $1.5M | No change |
| AORT Artivion Inc. | 0.19% | 48,481 | $1.1M | New |
| BBOT Bridgebio Oncology Therapeut | 0.17% | 130,628 | $995K | No change |
| TELA Tela Bio Inc. | 0.08% | 636,300 | $477K | No change |
| ADGM Adagio Medical Holdings Inc. | 0.08% | 698,989 | $455K | Reduce -45.8% |
| NMTC Neuroone Medical Technologie | 0.04% | 82,767 | $252K | No change |
| ENVB Enveric Biosciences Inc. | 0.04% | 180,000 | $248K | New |
| MODD Modular Medical Inc. | 0.02% | 26,190 | $118K | No change |
| QTI QT Imaging Holdings Inc. | 0.01% | 15,236 | $62K | New |
Options reported separately and not counted above: SLS puts ($18.2M), HIMS calls ($2.6M).
Other holdings (2): bonds, preferreds, convertibles and warrants · $2K (not counted above)
Total filed on the 13F, all lines: $583.5M.
Portfolio Sells Q1 2026 → Q2 2026
| CORT Corcept Therapeutics Inc. | Sold out | 0.00% | −3.92 |
| LIVN Livanova PLC | Sold out | 0.00% | −3.86 |
| DNTH Dianthus Therapeutics Inc. | Reduce -84.0% | 0.99% | −3.49 |
| WAY Waystar Holding Corp. | Reduce -43.6% | 3.26% | −2.45 |
| EMBC Embecta Corp. | Sold out | 0.00% | −2.35 |
| ICLR Icon PLC | Reduce -71.2% | 2.63% | −2.26 |
| ABVX Abivax SA-ADR | Sold out | 0.00% | −2.18 |
| HAE Haemonetics Corp. | Sold out | 0.00% | −1.79 |
| TFX Teleflex Inc. | Sold out | 0.00% | −1.63 |
| BMRN Biomarin Pharmaceutical Inc. | Sold out | 0.00% | −1.58 |
| ANIP Ani Pharmaceuticals Inc. | Reduce -63.4% | 1.38% | −1.56 |
| GPCR Structure Therapeutics Inc. | Sold out | 0.00% | −1.45 |
| BHVN Biohaven Ltd. | Sold out | 0.00% | −1.42 |
| MNPR Monopar Therapeutics Inc. | Sold out | 0.00% | −1.37 |
| CRNX Crinetics Pharmaceuticals Inc. | Sold out | 0.00% | −1.31 |
| EWTX Edgewise Therapeutics Inc. | Sold out | 0.00% | −1.22 |
| CELC Celcuity Inc. | Reduce -43.2% | 1.97% | −1.22 |
| CMPS Compass Pathways PLC | Sold out | 0.00% | −1.20 |
| QDEL Quidelortho Corp. | Sold out | 0.00% | −0.85 |
| REPL Replimune Group Inc. | Sold out | 0.00% | −0.79 |
| ABT Abbott Laboratories | Reduce -31.0% | 2.00% | −0.76 |
| OGN Organon & Co. | Sold out | 0.00% | −0.75 |
| SION Sionna Therapeutics Inc. | Reduce -56.6% | 0.96% | −0.74 |
| IRON Disc Medicine Inc. | Sold out | 0.00% | −0.60 |
| IART Integra Lifesciences Holding | Sold out | 0.00% | −0.52 |
| MMS Maximus Inc. | Reduce -7.0% | 6.59% | −0.51 |
| PRQR Proqr Therapeutics NV | Sold out | 0.00% | −0.46 |
| SI Shoulder Innovations Inc. | Sold out | 0.00% | −0.44 |
| KYMR Kymera Therapeutics Inc. | Sold out | 0.00% | −0.39 |
| CNTX Context Therapeutics Inc. | Sold out | 0.00% | −0.35 |
| OCUL Ocular Therapeutix Inc. | Reduce -44.3% | 0.91% | −0.27 |
| TARA Protara Therapeutic Inc. | Reduce -2.4% | 1.26% | −0.22 |
| HYPR Hyperfine Inc. | Sold out | 0.00% | −0.16 |
| ADGM Adagio Medical Holdings Inc. | Reduce -45.8% | 0.08% | −0.14 |
| AQST Aquestive Therapeutics Inc. | Reduce -22.7% | 1.06% | −0.09 |
| FHTX Foghorn Therapeutics Inc. | Sold out | 0.00% | −0.08 |
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −0.08 |
| ENTA Enanta Pharmaceuticals Inc. | Sold out | 0.00% | −0.07 |
| IMNM Immunome Inc. | Reduce -24.8% | 0.45% | −0.07 |
| VIR Vir Biotechnology Inc. | Reduce -28.3% | 1.88% | −0.06 |
| ZBIO Zenas Biopharma Inc. | Reduce -37.1% | 0.91% | −0.03 |
| BOLD Boundless Bio Inc. | Sold out | 0.00% | −0.03 |
| NYXH Nyxoah SA | Sold out | 0.00% | −0.02 |
| DRUG Bright Minds Biosciences Inc. | Reduce -14.1% | 0.89% | −0.02 |
| ERAS Erasca Inc. | Sold out | 0.00% | −0.01 |
| SLP Simulations Plus Inc. | Sold out | 0.00% | −0.00 |
| PMVP PMV Pharmaceuticals Inc. | Reduce -14.4% | 0.60% | +0.06 |
| OVID Ovid Therapeutics Inc. | Reduce -19.7% | 0.46% | +0.06 |
| ANTX AN2 Therapeutics Inc. | Reduce -19.4% | 0.44% | +0.12 |
| EYPT Eyepoint Inc. | Reduce -13.7% | 1.53% | +0.19 |
Portfolio Buys Q1 2026 → Q2 2026
| AVR Anteris Technologies Global | Add +3.0% | 9.36% | +5.06 |
| ALLO Allogene Therapeutics Inc. | New | 4.75% | +4.75 |
| GMED Globus Medical Inc. Class A | New | 4.09% | +4.09 |
| COR Cencora Inc. | Add +72.0% | 8.42% | +3.85 |
| IDYA Ideaya Biosciences Inc. | New | 3.07% | +3.07 |
| CI The Cigna Group | New | 2.73% | +2.73 |
| VTRS Viatris Inc. | New | 2.60% | +2.60 |
| ORKA Oruka Therapeutics Inc. | Add +33.7% | 2.89% | +1.95 |
| REGN Regeneron Pharmaceuticals | New | 1.92% | +1.92 |
| BMY Bristol-Myers Squibb Co. | New | 1.91% | +1.91 |
| MDT Medtronic PLC | New | 1.91% | +1.91 |
| HELP Cybin Inc. | New | 1.47% | +1.47 |
| SENS Senseonics Holdings Inc. | Add +1275.6% | 1.55% | +1.44 |
| ZBH Zimmer Biomet Holdings Inc. | Add +109.9% | 1.94% | +1.12 |
| TNGX Tango Therapeutics Inc. | New | 1.12% | +1.12 |
| SNY Sanofi-ADR | Add +52.0% | 2.66% | +1.00 |
| GSK GSK PLC-Spon ADR | Add +13.2% | 3.92% | +0.85 |
| AVAH Aveanna Healthcare Holdings | New | 0.54% | +0.54 |
| TYRA Tyra Biosciences Inc. | Add +14.8% | 3.81% | +0.46 |
| RLMD Relmada Therapeutics Inc. | Add +4.0% | 1.19% | +0.22 |
| AORT Artivion Inc. | New | 0.19% | +0.19 |
| SVRA Savara Inc. | Add +0.6% | 0.65% | +0.17 |
| ENVB Enveric Biosciences Inc. | New | 0.04% | +0.04 |
| QTI QT Imaging Holdings Inc. | New | 0.01% | +0.01 |
Options Activity Q1 2026 → Q2 2026
| SLS Sellas Life Sciences Group I | put | New | 1,230,700 | $18.2M |
| CNC Centene Corp. | put | Sold out | 100,000 | $3.3Mbefore exit |
| HIMS Hims & Hers Health Inc. | call | New | 75,000 | $2.6M |
| ELTX Elicio Therapeutics Inc. | put | Sold out | 11,700 | $125Kbefore exit |
| OSCR Oscar Health Inc. Class A | put | Sold out | 3,000 | $34Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 55 | $583.5M | AVR, COR, MMS, ALLO, GMED |
| Q1 2026 | 71 | $693.9M | MMS, WAY, ICLR, COR, DNTH |
| Q4 2025 | 63 | $603.1M | CELC, CI, SNY, MMS, ZBH |
| Q3 2025 | 49 | $395.1M | MMS, CELC, SNY, DNTH, ALKS |
| Q2 2025 | 47 | $249.1M | MMS, IRON, GMED, CNC, MRK |
| Q1 2025 | 51 | $330.2M | ICLR, MMS, MRK, ZBH, NBIX |
| Q4 2024 | 49 | $355.3M | ICLR, MMS, CI, LH, SNY |
| Q3 2024 | 35 | $223.1M | LH, TEVA, MMS, ZBH, VXRT |
| Q2 2024 | 43 | $265.1M | LH, TFX, ZBH, SNN, OGN |
| Q1 2024 | 45 | $287.0M | LH, CI, GMED, MDGL, GSK |